Propanc PRP Phase 1b: Execution Partnership Masks Absent Mechanistic Rationale and Zero Efficacy Precedent

Propanc Signs MOU with Avance Clinical for PRP Phase 1b Trial

Propanc Biopharma, Inc. has signed a Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd to support the clinical delivery of Propanc’s Phase 1b, First-In-Human (FIH) clinical trial for PRP, its lead investigational candidate for advanced solid tumors. This collaboration aims to efficiently advance PRP from FIH into Proof-of-Concept and later-phase development, leveraging Avance Clinical's extensive experience in early-phase oncology studies. The partnership also capitalizes on the unique advantages of the Australian market, including rapid ethics approval and a significant R&D tax rebate, to accelerate the pathway to clinical success. The planned study is designed to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity of PRP in patients with advanced cancer.

• Propanc Biopharma has entered into a strategic Memorandum of Understanding with Avance Clinical, a full-service Contract Research Organization, to facilitate the clinical delivery of its lead oncology candidate, PRP. This collaboration is a critical step in advancing PRP from preclinical development into its First-In-Human Phase 1b clinical study, with a shared commitment to scientific rigor and efficient progression towards later-phase development.
• The partnership is strategically positioned to leverage the unique benefits of the Australian clinical trial landscape. These advantages include an accelerated ethics approval process and access to the Australian R&D tax rebate, which can provide up to 43.5% off eligible research and development costs. This approach aims to provide Propanc with an efficient and cost-effective pathway for PRP's clinical evaluation and development.
• The planned Phase 1b FIH study for PRP is comprehensively designed to assess key parameters including safety, tolerability, pharmacokinetics, immunogenicity, and preliminary clinical activity in patients with advanced cancer. Avance Clinical brings expertise in early-phase oncology, including adaptive dose-escalation strategies and alignment with evolving regulatory expectations such as FDA Project Optimus, ensuring a robust data-driven foundation for PRP's continued development.

PRP's Strategic Path: Expanding Beyond Advanced Solid Tumors

PRP is being investigated across a broad and diverse range of clinical indications beyond advanced solid tumors, spanning musculoskeletal, urological, ophthalmological, dermatological, and wound-healing applications. The intervention models employed reflect varying levels of clinical evidence maturity, from proof-of-concept and case-control designs through to randomized controlled trials, meta-analyses, and phase II/III studies.

Addressing Critical Gaps in Advanced Solid Tumor Treatment

Despite meaningful advances in immuno-oncology and targeted therapy, substantial gaps remain in the management of advanced solid tumors across diverse patient populations. Recent literature highlights several underserved groups and systemic challenges that continue to drive unmet clinical need, spanning biological resistance mechanisms, patient vulnerability, and treatment access.

• Immunotherapy-refractory patients represent a critical unmet population, particularly those with tumors harboring immunosuppressive microenvironments enriched with M2-like macrophages. Novel approaches under investigation include dual-function antibodies targeting both PD-L1 and αvβ3, intratumoral delivery of combined PD-1/PD-L1 and CTLA-4 inhibitors, and CAF-targeting nanoparticle co-delivery systems — with the latter achieving tumor eradication without recurrence in 66.7% of preclinical TNBC models.

• Elderly patients (≥75 years) with advanced solid tumors remain underrepresented in immunotherapy trials, with limited evidence-based guidance on efficacy and safety. PRaG therapy — combining PD-1/PD-L1 inhibitors, radiotherapy, and GM-CSF — is being evaluated in a multicenter, prospective, single-arm Phase II trial (n=29), with preliminary findings suggesting both tolerability and clinical benefit in this age group.

• Frail patients with advanced cancer are at risk of receiving aggressive interventions beyond the point of meaningful benefit. Current literature advocates for integration of geriatric and palliative assessments, improved shared decision-making frameworks, and individualized approaches that balance clinical status, patient values, and goals of care.

• Patients with actionable genomic alterations who do not receive matched therapy constitute a substantial treatment gap: in a comprehensive genomic profiling cohort of 2,147 patients (NCT02290522, Rigshospitalet), actionable targets were identified in 57% of profiled patients, yet only 24% of those patients ultimately received biomarker-matched targeted therapy.

• Patients with high baseline tumor size (BTS) receiving biomarker-matched targeted therapy face disproportionately poor outcomes. In a study of 444 patients across early-phase clinical trials (January 2014–April 2021), lower BTS was independently associated with significantly longer PFS (6.2 vs. 3.3 months, P<0.001) and OS (21.2 vs. 6.7 months, P<0.001), despite similar ORR (28% vs. 22%, P=0.57).

• Patients requiring corticosteroids around ICI initiation represent an underrecognized subgroup with meaningfully reduced efficacy: steroid exposure within 30 days prior to the first ICI cycle was associated with a significantly lower objective response rate (20.3% vs. 36.7%, p<0.01), as was steroid use within the first 90 days of treatment (25.7% vs. 37.7%, p=0.01).

• Patients in resource-limited settings face substantial access barriers to immune checkpoint inhibitors. Ultra-low-dose nivolumab (20 mg IV every 2 weeks) is being evaluated as a strategy to expand global access while maintaining clinical efficacy.

• Long-term responders to immunotherapy or targeted therapy experience a distinct and underaddressed psychosocial burden — living in a "twilight zone" of neither patient nor healthy identity, managing ongoing uncertainty, fear of progression, and the need to adapt to a new normal — highlighting the need for tailored survivorship support and patient-individualized surveillance strategies.

• Patients who could benefit from optimized ICI administration timing remain underserved in current practice. A meta-analysis of 29 studies (n=6,129 patients) found that earlier time-of-day ICI administration was associated with improved OS (HR 0.60; 95% CI, 0.51–0.70) and PFS (HR 0.62; 95% CI, 0.54–0.71) across multiple tumor types including NSCLC, gastric cancer, RCC, SCLC, and biliary tract cancer — findings that warrant prospective validation and potential standardization.

Accelerating Oncology's First Steps: A Strategic Australian Play

The journey of a novel therapeutic from discovery to patient care is long and arduous, with the First-In-Human (FIH) trial representing a critical gateway. For an investigational candidate targeting advanced solid tumors, this initial clinical evaluation is paramount, as it provides the first insights into how the drug behaves in humans, assessing its safety, tolerability, and preliminary signs of efficacy. The landscape of advanced solid tumors remains an area of high unmet medical need, where innovative approaches are desperately sought.

Propanc Biopharma's decision to initiate its Phase 1b FIH trial in Australia, in collaboration with Avance Clinical, highlights a strategic approach to accelerate drug development. Australia has emerged as an attractive hub for early-phase trials, primarily due to its efficient regulatory environment, which often allows for rapid ethics committee approvals, and its generous R&D tax rebate scheme. These advantages can significantly streamline the clinical pathway, potentially reducing the time and cost associated with bringing a novel therapy to the next stage of development. This strategic geographical choice, coupled with the expertise of a specialized Contract Research Organization in early-phase oncology, aims to optimize trial execution and data generation.

However, the inherent risks of early-stage oncology development cannot be overstated. FIH trials, by their nature, face high attrition rates; many compounds fail to progress due to unexpected safety concerns or a lack of sufficient clinical activity. While the specific mechanism or preclinical data for Propanc's candidate are not detailed, the general challenges observed in the development of other advanced solid tumor therapies, such as the need to establish a favorable therapeutic index, remain pertinent. The success of this Phase 1b study will be crucial in de-risking the asset, providing the necessary evidence to inform future development decisions, and potentially attracting further investment in a highly competitive therapeutic area. This move underscores the importance of strategic planning and robust execution in the challenging pursuit of novel cancer treatments.